These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 34612846)

  • 41. Intravenous methylprednisolone with or without tocilizumab in patients with severe COVID-19 pneumonia requiring oxygen support: A prospective comparison.
    Hamed DM; Belhoul KM; Al Maazmi NA; Ghayoor F; Moin M; Al Suwaidi M; Narainen M; Makki M; AbdulRahman M
    J Infect Public Health; 2021 Aug; 14(8):985-989. PubMed ID: 34153729
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Outcomes of tocilizumab therapy in severe or critical COVID-19 patients: A retrospective cohort, single-centre study.
    Abdelnaby H; Aboelhassan W; Al-Jarallah M; Rajan R; Dashti R; Zhanna KD; Alsaber AR; Abd El-Aleem A; Ashry I; Abdullah M; Mahmoud Fouad A
    Trop Med Int Health; 2021 Dec; 26(12):1689-1699. PubMed ID: 34601803
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A double blinded placebo controlled comparative clinical trial to evaluate the effectiveness of Siddha medicines, Kaba Sura Kudineer (KSK) & Nilavembu Kudineer (NVK) along with standard Allopathy treatment in the management of symptomatic COVID 19 patients - a structured summary of a study protocol for a randomized controlled trial.
    Srivastava A; Rengaraju M; Srivastava S; Narayan V; Gupta V; Upadhayay R
    Trials; 2021 Feb; 22(1):130. PubMed ID: 33573696
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Biomarker variation in patients successfully treated with tocilizumab for severe coronavirus disease 2019 (COVID-19): results of a multidisciplinary collaboration.
    Conrozier T; Lohse A; Balblanc JC; Dussert P; Royer PY; Bossert M; Bozgan AM; Gendrin V; Charpentier A; Toko L; Badie J; Mezher C; Roux MF; Kadiane-Oussou NJ; Contreras R; Kessler J; Mazurier I; Klopfenstein T; Zayet S
    Clin Exp Rheumatol; 2020; 38(4):742-747. PubMed ID: 32573419
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial.
    Alavi Darazam I; Hatami F; Rabiei MM; Pourhoseingholi MA; Moradi O; Shokouhi S; Hajesmaeili MR; Shabani M; Irvani SSN
    Trials; 2020 Oct; 21(1):880. PubMed ID: 33106183
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tocilizumab demonstrates superiority in decreasing C-reactive protein levels in hospitalized COVID-19 patients, compared to standard care treatment alone.
    Calderón-Ochoa C; Plamenov-Donchev N; Hernández-Quiñones F; Mendoza-López O; Hinojos-Gallardo LC; Longino-Gómez AJ; Hernádez-Saldaña R; Duque-Rodríguez J; Ishida-Gutiérrez MC
    Microbiol Spectr; 2024 Jun; 12(6):e0249823. PubMed ID: 38687065
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial.
    Vainio PJ; Hietasalo P; Koivisto AL; Kääriäinen S; Turunen J; Virtala M; Vuorinen J; Scheinin M
    Trials; 2021 Jan; 22(1):44. PubMed ID: 33430933
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Real-World Evidence to Supplement Randomized Clinical Trials: Tocilizumab for Severe COVID-19 Pneumonia vs. a Cohort Receiving Standard of Care.
    Skarbinski J; Fischer H; Hong V; Liu L; Yau VM; Incerti D; Qian L; Ackerson BK; Amsden LB; Shaw SF; Tartof SY
    Clin Pharmacol Ther; 2023 Nov; 114(5):1073-1081. PubMed ID: 37571812
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Randomized Double-Blinded Placebo Controlled Trial of Clazakizumab for the Treatment of COVID-19 Pneumonia With Hyperinflammation.
    Lonze BE; Spiegler P; Wesson RN; Alachkar N; Petkova E; Weldon EP; Dieter RA; Li Y; Quinn M; Mattoo A; Soomro I; Cohen SM; Leung S; Deterville CL; Landrum BM; Ali MI; Cohen DJ; Singer AL; Sen A; Chong E; Hochman JS; Troxel AB; Montgomery RA
    Crit Care Med; 2022 Sep; 50(9):1348-1359. PubMed ID: 35583232
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Outcome of COVID-19 patients with use of Tocilizumab: A single center experience.
    Zain Mushtaq M; Bin Zafar Mahmood S; Jamil B; Aziz A; Ali SA
    Int Immunopharmacol; 2020 Nov; 88():106926. PubMed ID: 32889236
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tocilizumab treatment in critically ill patients with COVID-19: A retrospective observational study.
    Huang E; Isonaka S; Yang H; Salce E; Rosales E; Jordan SC
    Int J Infect Dis; 2021 Apr; 105():245-251. PubMed ID: 33609773
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study.
    Moreno-Pérez O; Andres M; Leon-Ramirez JM; Sánchez-Payá J; Rodríguez JC; Sánchez R; García-Sevila R; Boix V; Gil J; Merino E
    J Autoimmun; 2020 Nov; 114():102523. PubMed ID: 32690352
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
    Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A
    Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nebulised surfactant for the treatment of severe COVID-19 in adults (COV-Surf): A structured summary of a study protocol for a randomized controlled trial.
    Dushianthan A; Clark H; Madsen J; Mogg R; Matthews L; Berry L; de la Serna JB; Batchelor J; Brealey D; Hussell T; Porter J; Djukanovic R; Feelisch M; Postle A; Grocott MPW
    Trials; 2020 Dec; 21(1):1014. PubMed ID: 33302976
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tocilizumab in critically ill COVID-19 patients: An observational study.
    Mushtaq MZ; Mahmood SBZ; Almas A; Ather Wasti S; Ahsan Ali S
    Int Immunopharmacol; 2022 Jan; 102():108384. PubMed ID: 34838490
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Assessment of the effectiveness of tocilizumab on mortality and progression to mechanical ventilation or intensive care in patients with COVID-19 admitted to a tertiary hospital.
    Pinilla Rello A; Magallón Martínez A; Vicente Iturbe C; Escolano-Pueyo A; Herranz Bayo E; Aguilo Lafarga I
    Eur J Hosp Pharm; 2024 Apr; 31(3):212-219. PubMed ID: 36150845
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
    Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tocilizumab in patients hospitalized with COVID-19 pneumonia: systematic review and meta-analysis of randomized controlled trials.
    Gupta S; Padappayil RP; Bansal A; Daouk S; Brown B
    J Investig Med; 2022 Jan; 70(1):55-60. PubMed ID: 34561232
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Delayed inflammation decrease is associated with mortality in Tocilizumab-treated critically ill SARS-CoV-2 patients: A retrospective matched-cohort analysis.
    Urbina T; Lavillegrand JR; Garnier M; Mekinian A; Pacanowski J; Mario N; Dumas G; Hariri G; Pilon A; Darrivère L; Fartoukh M; Guidet B; Maury E; Leblanc J; Chantran Y; Fain O; Lacombe K; Voiriot G; Ait-Oufella H
    Innate Immun; 2022 Jan; 28(1):3-10. PubMed ID: 35089113
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized Clinical Trial.
    Murai IH; Fernandes AL; Sales LP; Pinto AJ; Goessler KF; Duran CSC; Silva CBR; Franco AS; Macedo MB; Dalmolin HHH; Baggio J; Balbi GGM; Reis BZ; Antonangelo L; Caparbo VF; Gualano B; Pereira RMR
    JAMA; 2021 Mar; 325(11):1053-1060. PubMed ID: 33595634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.